Researchers have created a prototype system that uses a mathematical model to predict – and a portable inkjet technology to produce – precise medication dosages tailored for specific patients, an advance in personalized medicine that could improve drug effectiveness and reduce adverse reactions.
Drug makers now manufacture tablets based on clinical studies that determine the average recommended dose. Often this average falls outside of the optimal dose for a particular patient, but there is no way to precisely adjust the dosage except by trial and error.
“Pharmaceutical companies make one or two or three dosage levels, so people try breaking tablets in half and other methods to get to the right dosage,” said Gintaras “Rex” Reklaitis, Purdue University’s Burton and Kathryn Gedge Distinguished Professor of Chemical Engineering.
Delivering a more precise dosage improves the effectiveness of drugs and reduces potential side effects.
“Many drugs have a minimum effective level, so you need to meet that, and many of them have a toxic level,” he said. “The closer you get to it the more side effects there are.”
The new approach uses a combination of data and mathematics to determine the precise dosage. Two or three blood samples are drawn from the patient after a small quantity of the drug is administered. Data from those samples are combined with information from clinical studies of larger numbers of patients, and mathematical models are used to determine the proper dose for a particular patient.
Then, a portable technology dissolves or melts the drugs with polymers and uses “drop-on-demand” inkjet printing technology to deposit exact quantities onto tablets or films. Melting medications requires more careful control than simply dissolving them. However, melting could offer benefits over solutions, Reklaitis said. Many of the newest drugs are poorly soluble in the bloodstream. Precisely controlling temperatures during the melting procedure could allow drug makers to control the drug properties and increase solubility.
“We envision that in its final form the printing will be done in an automated fashion. The pharmacist could key in the dose, the machine prints 20 tablets, and off you go,” said Reklaitis, who is working with a team of researchers led by Arun Giridhar, an associate research scientist in the School of Chemical Engineering, and Poching DeLaurentis, a research scientist in Purdue’s Oncological Sciences Center.
The team has built a prototype and is working toward commercialization of a device, which is about the size of a large laser printer. Recent research findings are detailed in papers published this year in the Journal of Pharmaceutical Sciences and the journal Pharmacotherapy.
The dosage-prediction research was pioneered by Gary E. Blau, a visiting professor in the School of Chemical Engineering, who died earlier this year. It has been funded by the National Science Foundation.
One of the research papers focuses on the mathematical method for predicting a patient’s dose while the other describes the drop-on-demand technology applied to solvent-based systems, work that has been supported under the NSF Engineering Research Centers (ERC) program.
“If we say the patient needs 23 milligrams every eight hours, there is no 23-milligram tablet on the market,” Giridhar said. “I can make a 23-milligram dose, but to make something that small and that precise is challenging to do with powders. It is much easier to dissolve or melt the drug formulation. Both are viable technologies.”
In personalized medicine, physicians use diagnostic methods to determine the precise therapy for each patient.
“We are saying that’s great, but you are still faced with the problem of how to administer the drug,” said Reklaitis, deputy director of an NSF ERC formed in 2006 to improve the way pharmaceuticals, foods and agricultural products are developed and manufactured.
“In the past, we haven’t had the mathematical tools to do this.”
DeLaurentis focuses on the mathematical and statistical methods required to determine the drug dosage, building on research initiated by Blau, Reklaitis and former postdoctoral research associate Jose M. Lainez. Giridhar is leading research to develop the portable system with doctoral student Elcin Icten. The work on the printing device also is supported by the Indiana Next Generation Manufacturing Competitiveness Center – IN-MaC – led by Purdue to attract, retain and grow high-value manufacturing industries in the state.
Researchers are involved in clinical studies to learn how effective the procedure is.
The same strategy – using prediction methods coupled with limited blood sampling – could enable health care professionals to monitor a drug’s effectiveness over time and adjust the dosage for the patient as needed.
The Latest on: Precise drug dosages
via Google News
The Latest on: Precise drug dosages
- South Africa pulls 2 million doses of JJ vaccine after contamination concernson June 13, 2021 at 6:10 pm
South Africa, which is struggling to roll out its inoculation program as it enters a third wave of the coronavirus pandemic, said Sunday it will pull two million of doses of the Johnson & Johnson (JJ) ...
- S.Africa pulls two million doses of J&J vaccineon June 13, 2021 at 1:40 pm
South Africa, which is struggling to roll out its inoculation programme as it enters a third wave of the coronavirus pandemic, said Sunday it will pull two million of doses of the Johnson & Johnson ...
- Covid-19: South Africa pulls two million doses of Johnson & Johnson vaccineon June 13, 2021 at 5:33 am
J&J did not reveal the precise number of doses in each batch, but they are known to correspond to several million jabs.
- South Africa pulls two million doses of Johnson & Johnson vaccineon June 13, 2021 at 4:14 am
Johannesburg: South Africa, which is struggling to roll out its inoculation programme as it enters a third wave of the coronavirus pandemic, said Sunday it will pull two million of doses of the ...
- South Africa pulls millions of doses of J&J vaccineon June 13, 2021 at 4:13 am
South Africa, which is struggling to roll out its inoculation programme as it enters a third wave of the coronavirus pandemic, said Sunday it will pull millions of doses ...
- US: 60 million J&J vaccine doses from troubled plant can’t be usedon June 12, 2021 at 8:00 am
The US Food and Drug Administration said Friday it had told Johnson Johnson that millions of doses of COVID vaccine produced at a troubled plant cant be used because of possible contamination issues.
- US Tells J&J Millions Of Vaccine Doses From Troubled Plant Can't Be Usedon June 11, 2021 at 5:03 pm
The US Food and Drug Administration said Friday it had told Johnson & Johnson that millions of doses of Covid vaccine produced at a troubled plant can't be used because of possible contamination ...
- US tells J&J millions of Covid-19 vaccine doses from troubled plant can't be usedon June 11, 2021 at 1:24 pm
The US Food and Drug Administration (FDA) said on Friday (June 11) it had told Johnson & Johnson that millions of doses of Covid-19 vaccine produced at a troubled plant can't be used because of ...
- Cardinal Health™ Nuclear & Precision Health Solutions Receives U.S. Food and Drug Administration Approval for New LYMPHOSEEK® Pediatric Indicationon June 9, 2021 at 11:13 pm
Cardinal Health (NYSE: CAH) today announced that LYMPHOSEEK ® (technetium Tc 99m tilmanocept) injection – the first and only radiopharmaceutical agent specifically designed for targeted lymphatic ...
- Sutro Biopharma Announces Additional Data for Dose-Escalation Phase 1 Study of STRO-002 to be Presented at ASCO 2021on May 19, 2021 at 2:28 pm
The dose-escalation data positions ... is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next ...
via Bing News